Publicly-traded company Clovis Oncology Inc. (NASDAQ:CLVS) had a closing price of $4.32 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $16.67, this means that the stock is underpriced by 74.09%. In the past 52 weeks the company’s stock price has moved within the range of $2.93 to $32.05.
This particular stock’s 5-day moving average is 3.77, its 20-day moving average is 3.45 and its 100-day moving average is 7.28. Clovis Oncology Inc. (CLVS) currently has 53.03M shares outstanding, which means that its market capitalization is $229.08M.
The Details: Clovis Oncology Inc. (CLVS) Financial Health
Return on Assets is a number, expressed as a percentage that tells us how well a publicly-traded company is using its current assets to generate revenue. The higher the percentage, the better a company is using its assets to turn a profit. At the moment, Clovis Oncology Inc. Return on Assets is -49.10%.
What Does Wall Street Say about Company?
When choosing stocks, many investors search for what Wall Street professionals think about the company first – like what the average rating is. At the moment, the average analyst rating for CLVS is Overweight. Out of 11 total analysts who were surveyed, 1 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 5 rated it hold, and 5 rated it a Buy.
Understanding Profitability at Clovis Oncology Inc. (CLVS)
Taking a look at a public company’s Earnings per Share (EPS) is a good way of evaluating its profitability. In the most recent financial results released by Clovis Oncology Inc., for the quarter ending on 09/2019, the company posted EPS of -1.92. The average estimate of Wall Street analysts had projected -1.64.
Wall Street analysts, on average, are forecasting the company’s EPS to be -1.89, compared to -1.71 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 8 analysts is 35.84M – compared to 22.76M posted in the year-ago period.